PMID- 10079381
OWN - NLM
STAT- MEDLINE
DCOM- 19990708
LR  - 20191103
IS  - 1219-4956 (Print)
IS  - 1219-4956 (Linking)
VI  - 5
IP  - 1
DP  - 1999
TI  - Primary endometrioid carcinoma of fallopian tube. Clinicomorphologic study.
PG  - 61-6
AB  - Twenty cases of primary Fallopian tube endometrioid carcinoma (PFTEC) are 
      presented in the paper. This accounts for 42.5% of all histologic forms of 
      primary Fallopian tube carcinoma (PFTC) found in our Department. The youngest 
      patient was 38, and the oldest 68 years (mean: 56 years). Seven patients were 
      nulliparas. Only two cases were bilateral. According to FIGO staging, 13 cases 
      were evaluated as stage I, 4 as II, and 3 as stage III. Due to the histologic 
      grading, 8 tumors were classified as well, 7 as moderately, and 5 as poorly 
      differentiated. In the time of preparation of the manuscript, 12 women were still 
      alive, 2 of them with recurrent disease. The follow-up of patients without 
      recurrence ranged from 4 to 120 months (median: 63). Eight patients had died 
      (survival time: from 4 to 65 months; median: 26). Metastases were found in 8 
      patients, especially to ovaries. In 14/20 cases of PFTEC various forms of tubal 
      wall invasion were observed. Blood or lymphatic vessels involvement was found in 
      9 patients. Six of them had died and one is alive with the symptoms of disease. 
      Immunohistochemical detection of the mutant form of p53 protein and oncogene 
      product, c-erbB-2, was studied in 17 cases. Nine patients exhibited simultaneous 
      p53 protein accumulation and c-erbB-2 expression. 2/9 of these patients are alive 
      with recurrent tumors and 4/9 died. Endometrioid carcinoma of the Fallopian tube 
      can be characterized by a tendency to superficial invasion of tubal wall and in a 
      half of the cases by invasion of vessels. The majority of these tumors were 
      diagnosed at an early stage tumors.
FAU - Rabczynski, J
AU  - Rabczynski J
AD  - Medical University of Wroclaw, Department of Pathology, Wroclaw, Poland.
FAU - Ziolkowski, P
AU  - Ziolkowski P
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Pathol Oncol Res
JT  - Pathology oncology research : POR
JID - 9706087
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/analysis
MH  - Carcinoma, Endometrioid/epidemiology/*pathology/secondary
MH  - Cell Differentiation
MH  - Disease Progression
MH  - Fallopian Tube Neoplasms/epidemiology/*pathology
MH  - Female
MH  - Follow-Up Studies
MH  - Genes, erbB-2
MH  - Genes, p53
MH  - Humans
MH  - Life Tables
MH  - Menopause
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Neoplasm Proteins/analysis
MH  - Neoplasm Recurrence, Local
MH  - Neoplasms, Multiple Primary/epidemiology/pathology
MH  - Ovarian Neoplasms/secondary
MH  - Parity
MH  - Poland/epidemiology
MH  - Receptor, ErbB-2/analysis
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Tumor Suppressor Protein p53/analysis
RF  - 26
EDAT- 1999/03/18 00:00
MHDA- 1999/03/18 00:01
CRDT- 1999/03/18 00:00
PHST- 1999/03/18 00:00 [pubmed]
PHST- 1999/03/18 00:01 [medline]
PHST- 1999/03/18 00:00 [entrez]
AID - 10.1053/paor.1999.0061 [doi]
PST - ppublish
SO  - Pathol Oncol Res. 1999;5(1):61-6. doi: 10.1053/paor.1999.0061.